Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Capital Expenditures (2016 - 2025)

Arrowhead Pharmaceuticals' Capital Expenditures history spans 15 years, with the latest figure at $159000.0 for Q4 2025.

  • For Q4 2025, Capital Expenditures fell 97.88% year-over-year to $159000.0; the TTM value through Dec 2025 reached $15.3 million, up 3443.75%, while the annual FY2025 figure was $22.7 million, 438.9% up from the prior year.
  • Capital Expenditures reached $159000.0 in Q4 2025 per ARWR's latest filing, down from $7.5 million in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $100.0 million in Q2 2023 to a low of -$95.8 million in Q2 2024.
  • Average Capital Expenditures over 5 years is $13.8 million, with a median of $7.5 million recorded in 2024.
  • The largest YoY upside for Capital Expenditures was 948.65% in 2023 against a maximum downside of 648.82% in 2023.
  • A 5-year view of Capital Expenditures shows it stood at $5.8 million in 2021, then soared by 573.43% to $38.9 million in 2022, then tumbled by 70.99% to $11.3 million in 2023, then crashed by 33.43% to $7.5 million in 2024, then tumbled by 97.88% to $159000.0 in 2025.
  • Per Business Quant, the three most recent readings for ARWR's Capital Expenditures are $159000.0 (Q4 2025), $7.5 million (Q3 2025), and $14.8 million (Q2 2025).